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A B S T R A C T
Background
Placing a small volume of colostrum directly onto the buccal mucosa of preterm infants during the early neonatal period may provide
immunological and growth factors that stimulate the immune system and enhance intestinal growth. These benefits could potentially
reduce the risk of infection and necrotising enterocolitis (NEC) and improve survival and long-term outcome.
Objectives
To determine if early (within the first 48 hours of life) oropharyngeal administration of mother’s own fresh or frozen/thawed colostrum
can reduce rates of NEC, late-onset invasive infection, and/or mortality in preterm infants compared with controls. To assess trials for
evidence of safety and harm (e.g. aspiration pneumonia). To compare effects of early oropharyngeal colostrum (OPC) versus no OPC,
placebo, late OPC, and nasogastric colostrum.
Search methods
We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled
Trials (CENTRAL; 2017, Issue 8),MEDLINEvia PubMed ( 1966 toAugust 2017), Embase ( 1980 toAugust 2017), and theCumulative
Index to Nursing and Allied Health Literature ( CINAHL; 1982 to August 2017). We also searched clinical trials registries for ongoing
and recently completed trials ( clinicaltrials.gov; the World Health Organization International Trials Registry ( www.whoint/ictrp/
search/en/), and the ISRCTN Registry), conference proceedings, and the reference lists of retrieved articles for randomised controlled
trials and quasi-randomised trials. We performed the last search in August 2017. We contacted trial investigators regarding unpublished
studies and data.
Selection criteria
We searched for published and unpublished randomised controlled trials comparing early administration of oropharyngeal colostrum
(OPC) versus sham administration of water, oral formula, or donor breast milk, or versus no intervention. We also searched for studies
comparing early OPC versus early nasogastric or nasojejunal administration of colostrum. We considered only trials that included
preterm infants at < 37 weeks’ gestation. We did not limit the review to any particular region or language.
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Data collection and analysis
Two review authors independently screened retrieved articles for inclusion and independently conducted data extraction, data analysis,
and assessments of ’Risk of bias’ and quality of evidence.We graded evidence quality using theGrading of Recommendations Assessment,
Development and Evaluation (GRADE) approach. We contacted study authors for additional information or clarification when
necessary.
Main results
We included six studies that compared early oropharyngeal colostrum versus water, saline, placebo, or donor, or versus no intervention,
enrolling 335 preterm infants with gestational ages ranging from 25 to 32 weeks’ gestation and birth weights of 410 to 2500 grams.
Researchers found no significant differences between OPC and control for primary outcomes - incidence of NEC (typical risk ratio
(RR) 1.42, 95% confidence interval (CI) 0.50 to 4.02; six studies, 335 infants; P = 0.51; I² = 0%; very low-quality evidence), incidence
of late-onset infection (typical RR 0.86, 95% CI 0.56 to 1.33; six studies, 335 infants; P = 0.50; I² = 0%; very low-quality evidence),
and death before hospital discharge (typical RR 0.76, 95% CI 0.34 to 1.71; six studies, 335 infants; P = 0.51; I² = 0%; very low-quality
evidence). Similarly, meta-analysis showed no difference in length of hospital stay between OPC and control groups (mean difference
(MD) 0.81, 95% CI -5.87 to 7.5; four studies, 293 infants; P = 0.65; I² = 49%). Days to full enteral feeds were reduced in the OPC
group with MD of -2.58 days (95% CI -4.01 to -1.14; six studies, 335 infants; P = 0.0004; I² = 28%; very low-quality evidence).
The effect of OPC was uncertain because of small sample sizes and imprecision in study results (very low-quality evidence).
No adverse effects were associated with OPC; however, data on adverse effects were insufficient, and no numerical data were available
from the included studies.
Overall the quality of included studies was low to very low across all outcomes. We downgraded GRADE outcomes because of concerns
about allocation concealment and blinding, reporting bias, small sample sizes with few events, and wide confidence intervals.
Authors’ conclusions
Large, well-designed trials would be required to evaluate more precisely and reliably the effects of oropharyngeal colostrum on important
outcomes for preterm infants.
P L A I N L A N G U A G E S U M M A R Y
Review question
Does providing a very small volume of maternal colostrum into the mouth of preterm babies (oropharyngeal colostrum (OPC)) prevent
complications and improve health outcomes?
Background
Placing a small volume of colostrum - the first milk produced by the mother during the first few days of life - directly onto the inside of
the cheeks of preterm infants may provide immunological and growth factors that stimulate the immune system and enhance growth
of the intestine. These benefits could potentially reduce infections, including severe infections in the intestine known as necrotising
enterocolitis (NEC), thereby improving survival and long-term outcomes.
Study characteristics
We searched for both published and unpublished studies comparing oropharyngeal colostrum versus a control such as water, placebo,
or no oral priming. We included only clinical trials reporting outcomes in preterm babies (< 37 weeks’ gestation). The evidence is up-
to-date as of August 2017. We did not limit the review to any particular region or language.
Key results
Six studies were eligible for inclusion, involving 335 preterm infants with gestational ages ranging from 25 to 32 weeks’ gestation and
birth weights of 410 to 2500 grams. Reviewers noted no differences between OPC and control for rate of NEC, infection, or death
before hospital discharge. Similarly, they observed no difference in length of hospital stay between OPC and control babies. Infants
who received OPC achieved full milk feeds on average 2.5 days earlier than those given placebo or no intervention. However, included
studies were small, data were insufficient, and study designs were not ideal. Combining study data did not provide sufficient evidence to
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recommend the use of colostrum for oral priming to prevent complications in preterm infants. Five of the included studies reported no
harms (adverse effects); however, no numerical data are available from these studies. Included studies were of very low quality; therefore
the effects of OPC remain uncertain.
Conclusions
Larger, better quality clinical trials would be needed to evaluate more precisely and reliably the effects of OPC on important outcomes
for preterm infants. .
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oropharyngeal colostrum (OPC) compared to control (water, saline, or no intervention) in preterm infants
Patient or population: preterm infants
Setting: neonatal intensive care unit
Intervention: oropharyngeal colostrum (OPC)
Comparison: control (water, saline, or no intervent ion)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control (wa-
ter, saline, or no inter-
vention)
Risk with oropharyn-
geal colostrum (OPC)
Incidence of necrot is-
ing enterocolit is (NEC)
Study populat ion RR 1.42
(0.50 to 4.02)
335
(6 RCTs)
⊕©©©
VERY LOWa,b
3 per 100 4 per 100
(2 to 12)
Incidence of late-onset
sepsis
Study populat ion RR 0.86
(0.56 to 1.33)
335
(6 RCTs)
⊕©©©
VERY LOWa,b,c
20 per 100 17 per 100
(11 to 26)
Death before discharge
to home
Study populat ion RR 0.76
(0.34 to 1.71)
335
(6 RCTs)
⊕©©©
VERY LOWd,e,f
6 per 100 5 per 100
(2 to 10)
Days to full enteral feed Mean time to full en-
teral feed was 10 to 25
days
MD 2.58 days lower
(4.01 lower to 1.14
lower)
- 335
(6 RCTs)
⊕©©©
VERY LOWb,d,e
A lower score indicates
a better outcome
Length of hospital stay
(days)
Mean length of hospital
stay was 47 to 86 days
MD 0.81 days higher
(5.87 lower to 7.5
higher)
- 293
(4 RCTs)
⊕©©©
VERY LOWa,g,h
A lower score indicates
a better outcome
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Pneumonia Study populat ion RR 2.08
(0.54 to 8.06)
57
(3 RCTs)
⊕⊕©©
LOWd,f
6 per 100
(3 to 52)
7 per 100
(1 to 45)
Reported adverse ef -
fects
No pre-def ined adverse ef fects have been de-
scribed by any studies. Adverse ef fects were
narrat ively reported as no adverse ef fects with
the intervent ion. No numerical data were pro-
vided. One study reported ‘‘no recorded episodes
of apnea, bradycardia, desaturat ion or other ad-
verse ef fects’’ but without def ining the adverse
ef fects. A second study stated that ‘‘no adverse
events were noted’’, and another mentioned in the
method sect ion that ‘‘apnea, bradycardia events
and aspirat ion pneumonia were charted accord-
ing to unit policy’’
- 335
(6 RCTs)
⊕©©©
VERY LOWa,d,i,j
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NEC: necrot ising enterocolit is; OPC: oropharyngeal colostrum; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aStudies with the highest weight involved concern about allocat ion concealment and blinding.
bSmall sample size. The conf idence interval was wide and crossed the line of no ef fect.
cThe study with the highest weight involved concern about method of randomisat ion.
d75% of the included studies were not blinded.
eTwo studies involved concerns about allocat ion concealment.
f Small sample size, variable ef fect size, and conf idence interval crossing the line of no ef fect.
gTwo studies involved concerns about blinding, and two provided incomplete outcome data (attrit ion bias).
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hI² was 47% - not high enough to lower our conf idence. Heterogeneity could be explained as one study had lower part icipant
gestat ional age and birth weight.
iA narrat ive report was provided without a clear statement of adverse ef fect; est imates are not precise.
jNeither def init ions of adverse ef fects nor methods used in monitoring were reported.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Preterm birth (before 37 weeks’ gestation) is one of the most
significant issues associated with perinatal health care (WHO
2012). Complications of preterm birth contributed to approxi-
mately 50% of neonatal deaths in 2016 and are the leading cause
of death before five years of age (Blencowe 2012; UN IGME
2017). The rate of preterm birth is increasing by an average of
1% per year worldwide; the World Health Organization (WHO)
estimated 12.9 million preterm births (9.6% of total live births)
in 2005 (Beck 2009), and 15 million (11.1% of total live births)
in 2010 (Blencowe 2013). Despite substantial advances in neona-
tal care, mortality and morbidity remain high in this population
(Goldenberg 2008; Slattery 2002).
Necrotising enterocolitis (NEC), a multi-factorial, life-threaten-
ing inflammatory condition of the gastrointestinal tract, affects
0.3% to 2.4% per 1000 live births, with 70% of cases occurring
in preterm infants (Hunter 2008; Thompson 2008). NEC is a
complex process involving inflammation and bacterial invasion of
the immature mucosa. Hypoperfusion of the bowel, use of antibi-
otics, and delay in commencing enteral feeding act synergistically
to promote intestinal atrophy and abnormal bacterial colonisation
of the bowel (Rodriguez 2015a; Westerbeek et al 2006). Late-on-
set infection (LOI), defined as a blood culture-positive microbial
infection after 72 hours of life (Stoll 2002), is associated with a
high burden of morbidity and mortality in preterm infants. De-
spite a variety of infection control measures and the use of antibi-
otics, preterm infants remain at high risk for infection and NEC,
both of which are associated with poor neurodevelopmental and
growth outcomes (Stoll 2004). These conditions are also linked
to prolonged hospital stays and substantial increases in the cost
of care for both hospitals and families (Bisquera 2002; Johnson
2013).
It has been suggested that oropharyngeal colostrum (OPC) is a
continuation of the exposure of the foetal oropharynx to growth
and protective biofactors of the amniotic fluid during foetal life.
Colostrum, the fluid secreted by the mammary glands over the
first few postnatal days, is rich in biological protective factors that
are present in higher concentrations in the colostrum of mothers
who have delivered preterm infants (Araújo 2005;Wheeler 2007).
Colostrummay act via differentmechanisms: as a local barrier that
prevents adhesionofmicrobes to themucosa,modulating cytokine
interaction with oropharyngeal-associated lymphoid tissues and
facilitating the absorption of immune factors by buccal mucosa;
through pre-biotic and anti-inflammatory actions; via antioxidant
properties of lactoferrin; and by stimulation of intestinal growth
and repair (Rodriguez 2009).
Description of the intervention
Oropharyngeal administration of the mother’s own colostrum to
her preterm infant consists of placing a small amount (0.1 to 0.5
mL) of colostrumdirectly onto the buccalmucosa at least once and
usually repeatedly within the first 48 hours of life. Oropharyngeal
administration can be performed by instilling colostrum inside
each cheek via syringe, or by gently painting the colostrum over
the tongue, around the gums, and along the lips using a sterile
swab soaked with 0.1 to 0.5 mL of colostrum, or any other means
such that fluid is absorbed by the buccal mucosa.
How the intervention might work
Human colostrum and milk are known to contain significant lev-
els of anti-infective agents (cytokines, lactoferrin, lysozymes, and
immunoglobulinA (IgA)) (Radillo 2013). Together,many of these
chemokines and trophic agents protect the infant from infection,
stimulate development of the gastrointestinal tract, and modu-
late the immune system of the infant (Chirico 2008). Many of
these factors are present in higher concentrations in the colostrum
secreted by mothers who have delivered preterm infants (Araújo
2005; Wheeler 2007). The oral cavity is a predominant site of mi-
crobial colonisation, and the oral mucosa is an important interface
between microbiota, immunologically active factors in colostrum,
and the infant’s immune system.When administered directly onto
the oropharyngeal mucosa, colostrum may provide benefit by act-
ing in three ways: (1) by stimulating the oropharyngeal-associated
lymphoid tissue system, (2) by promoting systemic absorption of
protective factors through the buccal mucosa, inducing systemic
immune responses, and (3) by acting as a barrier, blocking micro-
bial adhesion to the mucosa (Rodriguez 2009). In addition, the
high concentration of growth factors in colostrum, such as epider-
mal growth factor, may enhance intestinal growth and develop-
ment (Ballard 2013; Chang 2002). Substantial evidence indicates
that colostrum is a rich source of growth factors, immunoglob-
ulins, lactoferrin, cytokines, and other immunological active fac-
tors (Montagne 1999; Ustundag 2005;Walker 2010). Few studies
support OPC, although existing studies have suggested that it is a
safe, feasible prophylactic measure against sepsis, NEC, and venti-
lator-associated pneumonia (Gephart 2014; Lee 2015; Rodriguez
2010; Seigel 2013). Such immune-inflammatory modulation and
improved bowel growth may reduce rates of LOI and NEC, po-
tentially improving survival and neurodevelopmental outcomes in
preterm infants.
Why it is important to do this review
In the first few days of life, OPC is a novel, low-cost, simple to
administer intervention that may reduce NEC and sepsis. A sys-
tematic review of the evidence, including potential harms, is re-
quired before recommendations can be made for or against its use.
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This systematic review analysed the existing literature to collate
current evidence to determine if early (first 48 hours) OPC is safe
and feasible, and whether it affects important clinical outcomes in
preterm infants.
O B J E C T I V E S
To determine if early (within the first 48 hours of life) oropha-
ryngeal administration of mother’s own fresh or frozen/thawed
colostrum can reduce rates of NEC, late-onset invasive infection,
or mortality in preterm infants compared with controls. To assess
trials for evidence of safety and harm (e.g. aspiration pneumonia).
To compare effects of early oropharyngeal colostrum (OPC) ver-
sus no OPC, placebo, late OPC, and nasogastric colostrum.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all published randomised trials for which the unit
of randomisation was the infant, and cluster-randomised trials for
which the unit of randomisation was the neonatal unit. We ex-
cluded quasi-randomised and non-randomised trials such as con-
trolled before-and-after studies. We did not limit the review to any
particular region or language.
Types of participants
We included preterm infants (at less than 37 weeks’ gestation)
receiving care in any neonatal unit.
Types of interventions
We included the following interventions.
1. Oropharyngeal administration of mother’s own fresh or
frozen/thawed colostrum to preterm infants in the first 48 hours
of life, irrespective of when enteral feeding is initiated, what type
of milk is used for enteral feeding, or which feed advancement
regimen is applied.
2. Instillation of the colostrum inside the cheeks of the infant
by oral syringe or by gentle application over the tongue, around
the gums, and along the lips using a swab or sponge soaked with
a small amount of colostrum (0.1 to 0.5 mL), at least once and
usually repeatedly in the first 48 hours of life.
3. Any technique of oropharyngeal administration, such as
instillation by syringe, direct application to the oral mucosa by
swab, or any other means such that the fluid could be absorbed
by the buccal mucosa.
We considered studies comparing early administration of oropha-
ryngeal colostrum versus sham administration of water, oral for-
mula, or donor breast milk, or no intervention.We also considered
studies comparing OPC versus nasogastric or nasojejunal admin-
istration of colostrum.
We planned to perform three comparisons.
1. Early oropharyngeal colostrum versus sham administration
of water, oral formula, or donor breast milk, or no intervention.
2. Early oropharyngeal colostrum versus early nasogastric or
nasojejunal administration of colostrum.
3. Early oropharyngeal colostrum versus late (after 48 hours)
oropharyngeal colostrum .
This review identified only studies that compared early oropha-
ryngeal colostrum versus sham administration of water, normal
saline, oral formula, or donor breast milk, or versus no interven-
tion.
Types of outcome measures
Primary outcomes
1. Incidence of NEC (Bell’s stage 2 or 3) until discharge to
home (Walsh 1986)
2. Incidence of microbiologically confirmed late-onset
invasive infection until discharge to home, defined as a blood or
cerebrospinal fluid culture positive for microbial infection after
72 hours of life (Stoll 2002)
3. Death before discharge to home
Secondary outcomes
1. Pneumonia (chest X-ray changes/treated with at least five
days of antibiotics before discharge to home)
2. Chronic lung disease (defined as the need for oxygen
supplementation at 36 weeks’ postmenstrual age)
3. Retinopathy of prematurity (all stages and severe stage > 2)
(ICCROP 2005)
4. Death in the first year of life
5. Neurodevelopmental outcome at 18 to 24 months assessed
by clinician or parent-reported questionnaire
6. Formally reported adverse effects (e.g. aspiration, gagging/
choking on administration, bradycardia, desaturation, increase in
oxygen requirement, disturbances in vital signs) between start of
the intervention and discharge home
7. Weight gain from birth to discharge home (using weight
percentiles or Z-scores), time to regain birth weight
8. Length of hospital stay (days) from birth to discharge home
9. Days to full enteral feeds
10. Days of parenteral nutrition before discharge to home
11. Days of antibiotic therapy before discharge to home
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12. Receiving any breast milk at discharge to home
13. Receiving only breast milk (and not formula) at discharge
to home
Search methods for identification of studies
We used the criteria and standard methods of Cochrane and
Cochrane Neonatal (see the Cochrane Neonatal search strategy
for specialised register).
Electronic searches
We conducted a comprehensive search that included theCochrane
Central Register of Controlled Trials (CENTRAL; 2017, Issue 8)
in the Cochrane Library; MEDLINE via PubMed (1966 to Au-
gust 2017); Embase (1980 to August 2017); and the Cumulative
Index toNursing and AlliedHealth Literature (CINAHL; 1982 to
August 2017) using the following search terms: (colostrum), plus
database-specific limiters for RCTs and neonates (see Appendix 1
for the full search strategies for each database). We did not apply
language restrictions.
We searched clinical trials registries for ongoing or recently com-
pleted trials ( clinicaltrials.gov; the World Health Organization
International Trials Registry and Platform ( www.whoint/ictrp/
search/en/), and the ISRCTN Registry).
Searching other resources
We examined reference lists of included studies and previous re-
views. We searched proceedings of annual meetings of the Pae-
diatric Academic Societies (1993 to 2017), the European Society
for Paediatric Research (1995 to 2017), the Royal College of Pae-
diatrics and Child Health (2000 to 2017), the Perinatal Society
of Australia and New Zealand (2000 to 2017), and the National
Association of Neonatal Nurses.
Trials reported only as abstracts were eligible if sufficient informa-
tion to fulfil the inclusion criteria was available from the report or
upon contact with study authors.
We also searched the reference lists of any articles selected for
inclusion in this review to identify additional relevant articles.
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review
Group.
Selection of studies
We followed the standard processes recommended by theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Two review authors screened the title and abstract of all citations
identified through the search and independently assessed the full
text of all articles selected by the principal review author to deter-
mine which studies were eligible for inclusion. We resolved dis-
agreements by discussion until we reached consensus.
We contacted study authors for additional information or clarifi-
cation when necessary.
Data extraction and management
Two review authors independently extracted and compared data;
we resolved discrepancies through discussion and by consultation
with the third review author.
We used a modified Cochrane standard data collection sheet to
extract the following data from each study.
1. Study ID and contact details.
2. Method (design, duration of study, sequence generation,
allocation concealment, blinding).
3. Participants (total number, gestational age, sex, country,
socioeconomic and ethnic groups, diagnosis, status).
4. Intervention (number, time, technique, dose and duration,
any additional interventions).
5. Outcomes (time of outcome, reporting method, effect size).
We contacted study authors for additional information when re-
quired.
We have presented the included studies in Characteristics of
included studies tables.
Assessment of risk of bias in included studies
Two review authors (NA and SO) independently assessed the
risk of bias (low, high, or unclear) of all included trials using the
Cochrane ‘Risk of bias’ tool for the following domains (Higgins
2017).
1. Sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective reporting (reporting bias).
7. Any other bias.
We resolved disagreements by discussion or by consultation with a
third assessor (JD). See Appendix 2 for amore detailed description
of risk of bias for each domain.
Measures of treatment effect
We analysed treatment effects in individual trials using Review
Manager 5.3 (ReviewManager 2014); we have reported risk ratios
and risk differences for dichotomous data and mean differences
for continuous data, with respective 95% confidence intervals.
We also reported the number needed to treat for an additional
beneficial outcome or an additional harmful outcome for analyses
with statistically significant differences in the risk difference.
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Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials. An infant was considered only once per analysis.
Dealing with missing data
We contacted investigators when we identified important missing
data (in the outcomes) or unclear data. We performed intention-
to-treat analyses.
Assessment of heterogeneity
We observed heterogeneity between effect sizes of the included
studies by inspecting the forest plot and by using the Chi² test and
I² for heterogeneity (with P < 0.1).
We quantified inconsistency across studies to determine whether
heterogeneity was present and assessed its impact on the meta-
analysis using the equation I² = [(Q - df )/Q] × 100%, where Q is
the Chi² statistic and df is its degrees of freedom (Higgins 2011).
We used the percentage of variability in effect estimates to describe
inconsistency between trials that was due to heterogeneity rather
than to chance. We followed the guidelines recommended by the
Cochrane Neonatal Review Group for interpreting the I² statistic:
< 25% = none, 25% to 49% = low, 50% to 74% = moderate,
and > 75% = high heterogeneity. If we detected moderate or high
heterogeneity (I² > 50%), we explored possible causes (e.g. dif-
ferences in study design, participants, interventions, definitions,
measurement of outcome assessments).
Assessment of reporting biases
Although we planned to use a funnel plot to assess potential re-
porting bias, we did not do this, as we identified fewer than 10
trials.
Data synthesis
We performed the meta-analysis using Review Manager 5.3 and
the fixed-effect model for meta-analyses (Review Manager 2014).
For dichotomous data, we used Mantel-Haenszel for estimates of
typical risk ratio. For continuous data, we used the inverse variance
method for estimates of mean difference.We reported all estimates
with respective 95% confidence intervals.
Quality of evidence
We used the GRADE approach, as outlined in theGRADEHand-
book (Schünemann 2013), to assess the quality of evidence for the
following (clinically relevant) outcomes.
1. Incidence of NEC (Bell’s stage 2 or 3) until discharge to
home (Walsh 1986).
2. Incidence of microbiologically confirmed late-onset
invasive infection until discharge to home.
3. Death before discharge to home.
4. Length of hospital stay (days) from birth to discharge to
home.
5. Days to full enteral feed.
6. Pneumonia.
7. Formally reported adverse effects between start of the
intervention and discharge to home.
Two review authors independently assessed the quality of evidence
for each of the outcomes above. We considered evidence from
RCTs as high quality but downgraded the evidence one level for
serious (or two levels for very serious) limitations based upon the
following: design (risk of bias), consistency across studies, direct-
ness of evidence, precision of estimates, and presence of publica-
tion bias. We used the GRADEpro GDTGuideline Development
Tool to create a ’Summary of findings’ table to report the quality
of the evidence.
The GRADE approach yields an assessment of the quality of a
body of evidence by one of four grades.
1. High: we are very confident that the true effect lies close to
that of the estimate of the effect.
2. Moderate: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low: our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
4. Very low: we have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Subgroup analysis and investigation of heterogeneity
When substantial heterogeneity existed, we tested potential causes
through subgroup and sensitivity analyses.
If data were available, we planned to perform the following sub-
group analyses.
1. Infants born at < 30 weeks’ gestation.
2. Infants born at < 1500 grams.
3. Infants who were small for gestational age at birth (i.e. birth
weight < 10th centile).
Sensitivity analysis
Weplanned to perform sensitivity analyses to determine if findings
were affected by including only studies using adequate methods
(low risk of bias).
R E S U L T S
Description of studies
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Results of the search
We identified 14 study reports for full text screening (Alvarez
2016; Glass 2017; JPRN-UMIN000022923; Lee 2015; McFad-
den 2011 (see McFadden 2012); McFadden 2012; Montgomery
2008; NCT02912585; Rodriguez 2008 (see Rodriguez 2011);
Rodriguez 2011; Rodriguez 2015b; Romano-Keeler 2016; Sohn
2015; Zhang 2017). Of these, after translation of the abstract of
the report from Spanish, we found that one study was a non-
randomised trial (Alvarez 2016). Similarly, Montgomery 2008
was an observational study assessing the feasibility of oropharyn-
geal administration of mother’s colostrum. Rodriguez 2015b and
JPRN-UMIN000022923 were protocols for ongoing studies; we
have described both under Characteristics of ongoing studies. Two
were additional reports; one of these - McFadden 2011 was the
conference abstract for McFadden 2012, a PhD thesis that we
have included in this review. Rodriguez 2008 was the PhD thesis
for Rodriguez 2011, which we have included in this review. (See
Figure 1.) Two trials fulfilled all inclusion criteria for the review
except that colostrum was given after 48 hours of life (Lee 2015;
Zhang 2017). We have described these studies in the section on
Excluded studies and in the Characteristics of excluded studies ta-
ble. Six trials fulfilled the inclusion criteria of the review protocol:
Glass 2017; McFadden 2012; NCT02912585; Rodriguez 2011;
Romano-Keeler 2016; Sohn 2015. We conducted the last search
in August 2017.
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Figure 1. Study flow diagram.
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Included studies
We included six studies in the review: Glass 2017; McFadden
2012; NCT02912585; Rodriguez 2011; Romano-Keeler 2016;
Sohn 2015. All included studies compared administration of early
oropharyngeal colostrum versus sham administration of water,
placebo, or donor breast milk, or no intervention. Five studies
were published and one study was described in an unpublished
report that we obtained from the study author (NCT02912585).
We have presented features of these studies in the Characteristics
of included studies tables.
All included studies were small, single-centre trials involving a to-
tal of 335 infants with sample sizes ranging from 12 preterm in-
fants in Sohn 2015 to 149 in NCT02912585. Four studies pre-
specified prematurity with birth weight < 1500 grams as an in-
clusion criterion (Glass 2017; NCT02912585; Rodriguez 2011;
Sohn 2015). Two studies included only infants who were mechan-
ically ventilated (McFadden 2012; Sohn 2015). The gestational
age of included infants ranged from 25 to 32 weeks’ gestation with
birth weights between 410 and 2500 grams (see Table 1).
Interventions and comparisons
All six included studies commenced oropharyngeal administration
of mother’s own colostrum or placebo within 48 hours of birth.
Four studies administered 0.2 mL colostrum (or placebo) via sy-
ringe: 0.1 mL on each side of the oropharynx (NCT02912585;
Rodriguez 2011; Romano-Keeler 2016; Sohn 2015). Two stud-
ies, both open-label trials, used 0.2 mL colostrum for oral care
administered via “gentle swab along the inside of the mouth”
- in McFadden 2012 - or with a cotton-tipped applicator - in
Glass 2017. Two studies did not use placebo and provided no
additional intervention to participants randomised to the control
group (Romano-Keeler 2016; Sohn 2015). Three studies admin-
istered sterile water to infants in the control group (Glass 2017;
NCT02912585; Rodriguez 2011), and one study included two
control groups - one receiving sterile water and the other normal
saline (McFadden 2012). Researchers administered control inter-
ventions in a manner similar to administration of colostrum to
the intervention group.
Outcomes
All included studies reported the primary outcomes of the review
(NEC, LOI, and death before discharge to home) (Glass 2017;
McFadden 2012; NCT02912585; Rodriguez 2011; Romano-
Keeler 2016; Sohn 2015). Four studies defined NEC as Bell’s
stage 2 or 3 (Glass 2017; NCT02912585; Romano-Keeler 2016;
Sohn 2015), whereas two reports provided no specific diagnos-
tic criteria (McFadden 2012; Rodriguez 2011). Three studies de-
fined LOI as clinical signs and a positive blood culture (Glass
2017; NCT02912585; Sohn 2015). Glass 2017 provided addi-
tional criteria for defining LOI (onset after day three of life and
antibiotic therapy for at least five days), and three studies did not
provide a pre-determined definition (McFadden 2012; Rodriguez
2011; Romano-Keeler 2016). Included studies variably reported
secondary outcomes. All included studies followed up on partic-
ipants until hospital discharge, and no studies reported any later
outcomes.
Excluded studies
We excluded two studies because investigators provided oropha-
ryngeal colostrumafter 48hours of life (Characteristics of excluded
studies). Lee 2015 was a double-blind, placebo-controlled RCT
that included 48 infants born at < 28 weeks’ gestation who were
randomised to receive 0.2 mL of their mother’s colostrum or ster-
ile water (control) via the oropharyngeal route every three hours
for three days. However, most of the infants included in this study
received colostrum after 48 hours of life; thus we excluded this
study from the analysis. Similarly, Zhang 2017 was a double-blind,
placebo-controlled trial including 64 very low birth weight infants
(birth weight < 1500 grams) that compared administration of 0.1
mL of mother’s colostrum to each side of the cheek versus simi-
lar administration of normal saline. Mean age at the first dose of
colostrum or normal saline was > 48 hours in both groups; hence
we did not include this study in the review.
Risk of bias in included studies
Included studies were of variable quality (see Risk of bias in
included studies; Figure 2; Figure 3). All studies stated that treat-
ment was allocated randomly; however two reports did not specify
the method used to generate the random sequence (McFadden
2012; Sohn 2015). Similarly, two studies did not mention al-
location concealment methods (NCT02912585; Romano-Keeler
2016), and Glass 2017 reported that the allocation method was
not applicable. Only three studies were blinded and used opaque
syringes to deliver treatment (McFadden 2012; NCT02912585;
Rodriguez 2011). Study authors reported outcomes for most in-
fants in all studies, except Glass 2017, which did not report the
outcomes of 13 infants.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison
Oropharyngeal colostrum (OPC) compared to control (water,
saline, or no intervention) in preterm infants
Primary outcomes
Incidence of necrotising enterocolitis
All included studies reported the incidence of NEC in 335 infants.
Meta-analysis did not show an effect on the risk of NEC (typical
risk ratio (RR) 1.42, 95% confidence interval (CI) 0.50 to 4.02;
six studies, 335 infants; P = 0.51; Analysis 1.1; Figure 4). Two
studies had no cases of NEC (Rodriguez 2011; McFadden 2012),
so the estimate is based on four studies including 290 participants.
The typical risk difference was 0.01 (95% CI -0.03 to 0.06). We
noted no evidence of heterogeneity between studies (I² = 0%).
The quality of evidence was very low owing to imprecision and
high to unclear risk of bias.
Figure 4. Forest plot of comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), outcome: 1.1 Incidence of necrotising enterocolitis.
Incidence of late-onset infection
All included studies reported the incidence of LOI in 335 infants.
Meta-analysis did not show an effect on the risk of LOI (typical
RR 0.86, 95% CI 0.56 to 1.33; six studies, 335 infants; P = 0.50;
Analysis 1.2; Figure 5). We found no evidence of heterogeneity
between studies (I² = 0%). The quality of evidence was very low
owing to imprecision and high to unclear risk of bias.
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Figure 5. Forest plot of comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), outcome: 1.2 Incidence of late-onset infection.
Death before discharge to home
All included studies reported death before discharge home in 335
infants. Meta-analysis did not show an effect on the risk of death
before discharge home (typical RR 0.76, 95% CI 0.34 to 1.71; six
studies, 335 infants; P = 0.51; Analysis 1.3; Figure 6). One study
did not report death in any of the enrolled infants (Glass 2017),
so the estimate is based on five studies in 305 infants. No evidence
suggests heterogeneity between studies (I² = 0%). The quality of
evidence was very low owing to imprecision and high to unclear
risk of bias.
Figure 6. Forest plot of comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), outcome: 1.3 Death before discharge to home.
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Secondary outcomes
Days to full enteral feeds
All included studies reported days to full enteral feeds in 335
infants. Two studies reported that infants who received oropha-
ryngeal colostrum established full enteral feeds more quickly
(NCT02912585; Rodriguez 2011). The other included studies
did not show any statistically significant difference in this out-
come. Meta-analysis of the six included studies showed that in-
fants who received OPC within 48 hours of birth achieved full
enteral feeds earlier than those given placebo or no intervention
(mean difference (MD) -2.58, 95%CI -4.01 to -1.14; P = 0.0004;
Analysis 1.4; Figure 7). Heterogeneity was moderate (I² = 53%)
between studies. The quality of evidence was very low owing to
imprecision, high to unclear risk of bias, and moderate hetero-
geneity.
Figure 7. Forest plot of comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), outcome: 1.4 Days to full enteral feed.
Length of hospital stay
Four studies reported length of hospital stay in 293 infants
(McFadden 2012; NCT02912585; Rodriguez 2011; Romano-
Keeler 2016). Meta-analysis did not show an effect in the two
groups (MD 0.81, 95% CI -5.87 to 7.50; P = 0.81; Analysis 1.5).
Heterogeneity was moderate (I² = 49%) across studies. We ret-
rospectively explored this heterogeneity and identified one study
that included infants with a larger birth weight (McFadden 2012).
Exclusion of this study reduced heterogeneity to I² = 12% and did
not change the estimated effect in the meta-analysis for length of
hospital stay. The quality of evidence was very low owing to im-
precision, high to unclear risk of bias, and moderate heterogeneity.
Pneumonia
Meta-analysis did not show an effect on pneumonia (typical RR
2.08, 95% CI 0.54 to 8.06; three studies, 57 infants; P = 29)
(McFadden 2012; Rodriguez 2011; Sohn 2015). We found no
evidence of heterogeneity between studies (I² = 17%) (Analysis
1.6). The quality of evidence was very low owing to imprecision
and performance and selection bias.
Formally reported adverse effects (e.g. aspiration,
gagging/choking on administration, bradycardia,
desaturation, increase in oxygen requirement, disturbances
in vital signs) between start of the intervention and
discharge to home
Five studies mentioned adverse events (Glass 2017; McFadden
2012; NCT02912585; Rodriguez 2011; Romano-Keeler 2016),
but no studies reported the occurrence of any adverse events (ad-
ditional tables; Table 2). Researchers reported adverse events as
not occurring with the intervention and provided no numerical
data. The quality of evidence was very low owing to imprecision
and high to unclear risk of bias.
Chronic lung disease
Three studies reported chronic lung disease in 57 infants (
McFadden 2012; Rodriguez 2011; Sohn 2015). One study pro-
vided the definition of chronic lung disease (CLD) (oxygen re-
quired at 36 weeks’ corrected gestational age, or at discharge, if
sooner) (Sohn 2015). Meta-analysis did not show an effect on
the incidence of CLD (typical RR 0.85, 95% CI 0.60 to 1.20;
three studies, 57 infants; P = 0.84; Analysis 1.8). We noted no ev-
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idence of heterogeneity between studies (I² = 0%). Another study
reported bronchopulmonary dysplasia as an outcome but did not
define the diagnostic criteria used (NCT02912585). Including
this study in the meta-analysis did not change the result signifi-
cantly (typical RR 0.85, 95% CI 0.60 to 1.20; four studies, 206
infants; P = 0.37). Also, we noted no evidence of heterogeneity
between studies (I² = 0%). The quality of evidence was very low
owing to imprecision and performance and reporting bias.
Days of antibiotic therapy before discharge to home
Three studies reported days of antibiotic therapy in 141 infants
(McFadden 2012; Romano-Keeler 2016; Sohn 2015). Meta-anal-
ysis did not show an effect of administration of oropharyngeal
colostrum on the number of days of antibiotic therapy before dis-
charge home (MD 1.69, 95% CI -4.00 to 7.39; P = 0.65; Analysis
1.9).One trial found that infants who received oral care with saline
or sterile water (control) required fewer days of antibiotic therapy
when compared with those who received oral care with colostrum
(McFadden 2012). Heterogeneity (I² = 91%) between studies was
very high.We retrospectively explored this heterogeneity and iden-
tified that one study enrolled infants with a larger birth weight
(McFadden 2012). Excluding this study removed the heterogene-
ity but did not change the effect estimate. The quality of evidence
was very low owing to imprecision, performance and reporting
bias, and high heterogeneity.
Receiving any breast milk at discharge to home
One study reported on 99 infants receiving any breast milk at dis-
charge home (Romano-Keeler 2016). The study author divided
this outcome between those on unfortified breast milk and those
on fortified breast milk. Results show no statistically significant
differences between OPC and control groups for either type of
feeding, that is, receiving any fortified breast milk at discharge
(RR 0.67, 95% CI 0.44 to 1.02; one study, 99 infants; P = 0.06)
and receiving any unfortified breast milk at discharge (RR 0.98,
95% CI 0.89 to 1.07; one study, 99 infants; P = 0.60). However,
combining these outcomes revealed an effect (P = 0.04) of OPC
on infants receiving any breast milk (fortified or unfortified) com-
pared with controls. The quality of evidence was very low because
data were obtained from only one unblinded study with a small
sample size.
Receiving only breast milk (and not formula) at discharge to
home
One study reported on infants receiving only breast milk at dis-
charge to home (Romano-Keeler 2016). Researchers reported no
effect of OPC on infants receiving only breast milk (unfortified) at
discharge (RR 0.98, 95% CI 0.89 to 1.07; one study, 99 infants;
P = 0.60). The quality of evidence was very low because data were
obtained from only one unblinded study with a small sample size.
Days of parenteral nutrition before discharge to home
Two studies reported days of parenteral nutrition in 179 infants
before discharge to home (Glass 2017; NCT02912585). Meta-
analysis showed no difference in days of parenteral nutrition be-
tween infants who received oropharyngeal colostrum and those
given control interventions (MD 0.37, 95% CI -1.78 to 2.52;
two studies, 179 infants; P = 0.7; Analysis 1.11). We found no
evidence of heterogeneity between studies (I² = 0%). The quality
of evidence was very low owing to imprecision and performance
and reporting bias.
Weight gain from birth to discharge home (using weight
percentiles or Z-scores), time to regain birth weight
One unpublished study reported the outcome of weight at dis-
charge home in 149 infants (NCT02912585). This study showed
no effect of OPC on weight at discharge (MD -15.00, 95% CI -
50.83 to 20.83; P = 0.60). The quality of evidence was very low
owing to imprecision, unclear selection and reporting bias, and
the fact that data were obtained from only one study.
Retinopathy of prematurity (ROP)
Two studies reported ROP in 165 infants (NCT02912585;
Rodriguez 2011 as reported in Rodriguez 2008). Meta-analysis
did not show a statistically significant effect of the intervention
on the incidence of ROP (typical RR 0.98, 95% CI 0.33 to 2.94;
two studies, 165 infants; P = 0.98; Analysis 1.13). We noted no
heterogeneity between studies (I² = 0%). The quality of evidence
was very low owing to imprecision and performance and reporting
bias.
Death in the first year of life
None of the included studies reported death in the first year of
life.
Neurodevelopmental outcome at 18 to 24 months assessed
by clinician or parent-reported questionnaire
None of the included studies reported this outcome.
D I S C U S S I O N
Summary of main results
Review authors identified six randomised controlled trials (RCTs)
that were eligible for inclusion in this review. These studies re-
ported a range of outcomes. All six studies reported the three
primary outcomes in this review, and available trial data do not
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provide evidence that oropharyngeal administration of colostrum
compared with placebo (saline or sterile water) or no intervention
reduces the risk of late-onset infection (LOI), necrotising entero-
colitis (NEC), or death before discharge home in preterm infants.
However, all six studies were small and included a total of 335 par-
ticipants; this is likely to be insufficient to demonstrate small but
clinically important effects in these important outcomes. One on-
going study (see Characteristics of ongoing studies) aims to recruit
and follow up 489 extremely preterm infants with birth weight <
1250 grams, within the infant’s first 96 hours of life (Rodriguez
2015b). When available, including the findings of this study in
the meta-analysis may alter the estimates of effects and the con-
clusions.
Infants who received oropharyngeal colostrum established full en-
teral feeding sooner than those who received placebo or no in-
tervention. Despite this, the included studies do not show con-
sistent evidence of effect on length of hospital stay. In addition,
we considered several secondary outcomes in this review, and the
included studies do not demonstrate any effects on risk of pneu-
monia, chronic lung disease, or retinopathy of prematurity. They
also show no differences in weight at discharge, days of antibiotic
therapy, days on parenteral nutrition, or chances of receiving any
breast milk at the time of discharge. None of the included studies
followed up with participants beyond hospital discharge, and no
data were available to assess the effect of the intervention on death
by one year of age nor on neurodevelopmental outcome at 18 to
24 months of age.
These studies narratively reported adverse events and described
no adverse events related to administration of oropharyngeal
colostrum or placebo.
Overall completeness and applicability of
evidence
Most participants were very or extremely preterm infants with
very low birth weight. None of the included studies specified as
exclusion criteria small for gestational age or in utero compromise
such as absent end-diastolic flow onmaternal dopplers. One study
reported that five of 30 participants were small for gestational age
(Glass 2017). Most studies included ventilated infants, and only
Rodriguez 2011 specified the need for “vasopressor medications at
a dosage of > 10microg/kg/min” as an exclusion criterion. There-
fore, review findings should be applicable to most preterm and
very low birth weight babies.
Quality of the evidence
The GRADE quality of evidence was low and was downgraded
to very low owing to concerns about allocation concealment and
blinding in the highest weighted studies, concerns about incom-
plete outcome data, small sample sizes with few events, and wide
confidence intervals crossing the line of no effect for almost all
outcomes (see Summary of findings for the main comparison).
Studies showed heterogeneity in days to full feeds, which could
be due to variability between studies in the definition of time to
reach full enteral feeds (100 to 150 mL/kg/d). Although results
show a statistically significant effect and a moderate effect size, the
confidence interval was very wide (-4.01 to -1.14).
Potential biases in the review process
Our main concern with the review process is the possibility of
publication bias, as we identified insufficient studies to prepare a
funnel plot to assess this. We attempted to minimise this bias by
screening the reference lists of included trials and by searching for
abstracts and proceedings of major perinatal conferences. Another
major concern was incomplete reporting of results. We endeav-
oured to minimise this by contacting study authors when needed,
several of whomprovidedmissing data that we have reported in the
review. Although most data included in the analyses were derived
from study reports (published or unpublished) and additional in-
formation was provided by study authors, NCT02912585 pre-
sented continuous outcomes as median and interquartile range
(IQR), and mean and standard deviation (SD) were not available
on request. We therefore assumed a normal distribution and esti-
mated mean ± SD using the formula: IQR = approximately 1.35
of the SD (Cochrane Handbook for Systematic Reviews of Interven-
tions; Section 7.7.3.5; Higgins 2011a).
Agreements and disagreements with other
studies or reviews
This review focuses on oropharyngeal administration of mother’s
own colostrum within the first 48 hours of life and, to the best
of our knowledge, is the first review based on Cochrane system-
atic methods. Gephart 2014 conducted a systematic review to as-
sess the effect of oral therapy with colostrum compared with no
colostrum in sick neonates; findings of this review were generally
consistent with our review findings. Review authors reported lack
of strong evidence to support the proposed clinical benefits of early
colostrum oral care in sick neonates; they cited earlier studies sup-
porting the safety and feasibility of the use of colostrum, but these
studies used different study design methods, including RCTs, ob-
servational, cross-sectional, and longitudinal studies, and clinical
audits.
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Implications for practice
Limited available evidence currently suggests that oropharyngeal
administration of mother’s colostrum starting within the first 48
hours of life does not reduce the risk of NEC, late-onset infection,
or death until discharge in preterm infants, including very preterm,
very low birth weight infants. This approach can shorten the time
taken to achieve full enteral feeds but does not reduce the duration
of hospital stay. Results now awaited from an ongoing study may
alter these conclusions.
Implications for research
Although it is biologically plausible that oropharyngeal admin-
istration of mother’s colostrum can reduce the risk of late-onset
infection and NEC in preterm infants, additional, larger RCTs
are required to conclusively answer these questions. These trials
need to be adequately powered to assess effects of the intervention
on clinically relevant outcomes, including late-onset infection and
NEC. A priori agreements on dose and procedure for administra-
tion of oropharyngeal colostrum, inclusion of the most immature
and smallest (including growth-restricted) infants with other in-
tensive care needs (such as mechanical ventilation and inotropic
support), and well-defined, objective, and clinically relevant out-
come measures will enable wider application of the evidence to
groups at greatest risk. In addition, trials should aim to assess long-
term outcomes, principally mortality and neurodevelopment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Glass 2017
Methods Open label, placebo-controlled, randomised, controlled trial
Participants 30 infants (17 intervention and 13 control)
Inclusion criteria: birth weight < 1500 grams, born in the same hospital
Exclusion criteria: infants with major congenital anomalies or chromosomal syndromes
incompatible with life, infants of mothers not willing to provide colostrum for their
infant in the first week of life, infants of mothers with known human immunodeficiency
virus, hepatitis B, or hepatitis C
Setting: NICU, Children’s Hospital, Penn State Milton S. Hershey Medical Center,
Hershey, Pennsylvania, USA
From January 2011 to January 2016
Interventions With a cotton-tipped applicator, 0.2 mL of mother’s own colostrum was applied to the
infant’s oropharyngeal mucosa every 3 hours for 5 days from day 2 to day 7 of life
(intervention) vs 0.2 mL sterile water delivered in a similar manner (control)
Outcomes Change in salivary secretory IgA concentration from baseline to 2 weeks of age
Necrotising enterocolitis (Bell’s stage 2 or 3)
Culture-positive sepsis
Time to full enteral feeding (defined as 140 mL/kg/d)
Funding source Children’s Miracle Network Research Grant
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the
National Institutes of Health under award number 1R01DK099350. USA
Notes Results were initially available as a conference abstract, and further information was
provided by Dr Karen Glass. Data included in the review included information from
the subsequent publication - Glass 2017 - and information provided by Dr Glass
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random number generation”; additional
information provided by the study author
Allocation concealment (selection bias) High risk “Not applicable”; additional information
provided by the study author
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial was not blinded
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Glass 2017 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The trial was not blinded
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The trial was not blinded. but death is un-
likely to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 13 participants were excluded and were not
analysed. This was determined through ad-
ditional information provided by the study
author
Incomplete outcome data (attrition bias)
Length of hospital stay
Low risk This outcome has not been reported in this
trial
Selective reporting (reporting bias) High risk Proposed outcomes as
given in the study protocol (clinicaltrials.
gov NCT01443091) were reported. How-
ever, the estimated sample size in the pro-
tocol was 60 infants, although the report
included only 30 infants. No explanation
for this was provided
McFadden 2012
Methods Open-label, randomised, controlled trial
Participants 29 infants (11 intervention and 18 control)
Inclusion criteria: gestational age 26 to 34 weeks, admission to NICU, intubation and
mechanical ventilation, support with nasal continuous positive airway pressure (NCPAP)
Exclusion criteria: age > 24 hours, major congenital anomalies, infants diagnosed with
infection in the first 24 hours of life or born to mothers with active infection, parental
refusal, mothers not speaking English, mothers not wishing to breastfeed
Setting: The Woman’s Hospital of Texas, Houston, Texas, USA. From August 2011 to
January 2012
Interventions Oral care (gentle swirl of swab along inside of mouth - wiping cheeks, tongue, palate,
and lips every 3 to 6 hours, or more often as indicated) using colostrum/human milk
(intervention) or sterile water (control A) or normal saline (control B)
Outcomes Oral colonisation (oral culture) and time to oral colonisation
Necrotising enterocolitis (diagnostic criteria not specified)
Ventilator-associated pneumonia (diagnosed by increasing oxygen or ventilatory require-
ment and X-ray changes)
Duration of antibiotics (days)
Days to reach full enteral feeds
Length of hospital stay (days)
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McFadden 2012 (Continued)
Chronic lung disease (diagnostic criteria not specified)
Funding source The Woman’s Hospital of Texas, USA
Notes No protocol was available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Once consent was signed, a study envelope
was drawn for randomization and a study
number was assigned”
No other detail of the randomisation meth-
ods were given
Allocation concealment (selection bias) Low risk “by drawing an envelope with the designa-
tion sealed inside” and “Once consent was
signed, a study envelope was drawn for ran-
domization and a study number was as-
signed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was not blinded
“Staff were informed whether the subject
was assigned as control group A (ster-
ile water) or B (normal saline) or group
C (treatment: colostrum/human milk), as-
signed groupwas documented on the patient
kardex in the chart and a sign placed on the
infants chart to indicate study participation
and the assigned group”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was not blinded
“Staff were informed whether the subject
was assigned as control group A (ster-
ile water) or B (normal saline) or Group
C (treatment: colostrum/human milk), as-
signed groupwas documented on the patient
kardex in the chart and a sign placed on the
infants chart to indicate study participation
and the assigned group”
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The study was not blinded, but death is un-
likely to be influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three infants were still in the hospital when
the study was completed and were not in-
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McFadden 2012 (Continued)
cluded in the analysis
Incomplete outcome data (attrition bias)
Length of hospital stay
High risk Three infants were still in the hospital when
the study was completed and were not in-
cluded in the analysis
Selective reporting (reporting bias) Unclear risk No protocol was available
NCT02912585
Methods Double-blinded, randomised, placebo-controlled trial
Participants 149 infants (81 intervention and 68 control)
Inclusion criteria: birth weight < 1500 grams, gestational age < 34 weeks
Exclusion criteria: congenital anomalies, gastrointestinal disorders, maternal history of
substance abuse, positive HIV status
Setting: NICU, Clinics Hospital of Federal University of Uberlandia, Minas Gerais,
Uberlandia, Brazil. From 15 July 2013 to 15 July 2015
Interventions Oropharyngeal administration of own mother’s colostrum (intervention) vs sterile water
(control) using the same protocol as in Rodriguez 2011
Outcomes Incidence of proven sepsis (late-onset sepsis) defined as bacterial growth in blood culture
in a neonate with signs of clinical sepsis
Serum and urine IgA levels
Death before discharge
Necrotising enterocolitis (Bell’s stage 2 or 3)
Bronchopulmonary dysplasia (diagnostic criteria not specified)
Retinopathy of prematurity (grade 3)
Length of hospital stay (days)
Funding source Supported by TheMinas Gerais State Research Support Foundation (FAPEMIG), Brazil
Notes This study is not published yet but has been submitted for publication by the Journal
of Pediatrics. Results and further information provided by Dr Daniela Marques de Lima
Mota Ferreira (April 2017)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random number generation.
Additional information provided by study
author: “a randomization schedule of 30
infants by computer considering 15 num-
ber 1 (colostrum group) and 15 number 2
(placebo group)”
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NCT02912585 (Continued)
Allocation concealment (selection bias) Unclear risk No details were provided regarding alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study reported: “Clinical and research
staff remained unaware of study group
assignments, except one independent re-
search member, from the human milk
bank, who prepared the colostrum and
placebo syringes”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study reported: “Clinical and research
staff remained unaware of study group
assignments, except one independent re-
search member, from the human milk
bank, who prepared the colostrum and
placebo syringes”
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The study reported: “Clinical and research
staff remained unaware of study group
assignments, except one independent re-
search member, from the human milk
bank, who prepared the colostrum and
placebo syringes”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The study reported: “Thirty two random-
ized to colostrum group were excluded be-
cause own mother’s colostrum were not
available”
These 32 infants were excluded from the fi-
nal analysis of data. Additional information
regarding this group was provided by the
study author, and intention-to-treat analy-
sis was conducted in the meta-analysis
Incomplete outcome data (attrition bias)
Length of hospital stay
Low risk The study reported: “Thirty two random-
ized to colostrum group were excluded be-
cause own mother’s colostrum were not
available”
These 32 infants were excluded from the fi-
nal analysis of data. Additional information
regarding this group was provided by the
study author, and intention-to-treat was
conducted in the meta-analysis
Selective reporting (reporting bias) Unclear risk The trial has not been published. Data
have been provided by the trial’s investiga-
tor on request. Pre-specified primary out-
comes within the study protocol were re-
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NCT02912585 (Continued)
ported (protocol was available at clinicaltri-
als.gov: NCT01776268). Secondary out-
comes were not listed in the protocol
Rodriguez 2011
Methods Blinded, placebo-controlled, randomised, controlled trial
Participants 16 infants (9 intervention, 7 control)
Inclusion criteria: birth weight < 1000 grams and/or gestation < 28 weeks; appropriate
weight for gestational age
Exclusion criteria: presence of congenital anomalies, gastrointestinal or renal disorders,
receipt of vasopressor medications at a dosage > 10 mcg/kg/min, maternal chorioam-
nionitis, history of substance abuse, positive HIV status
Setting: Level III neonatal unit, NorthShore University Hospital, Chicago, Illinois, USA
Interventions 0.2 mL of own mother’s colostrum (intervention) vs sterile water (control)
Using a syringe, 0.1 mL was administrated by placing the tip of the syringe into the
infant’s mouth, alongside the right buccal cavity, and directing it posteriorly towards the
oropharynx over a period of at least 2 minutes. An additional 0.1 mL was administered
similarly on the left side. The procedure was started within 48 hours of life and was
carried out every 2 hours for 48 consecutive hours
Outcomes Secretory immunoglobulin A, lactoferrin, and interleukin-10
Necrotising enterocolitis (diagnostic criteria not specified)
Chronic lung disease (diagnostic criteria not specified)
Death before discharge
Pneumonia and bacteraemia
Retinopathy of prematurity (data provided by Dr Nancy Rodreiguez; diagnostic criteria
not specified)
Days to full enteral feeds, days to full per oral feeds, and days to full per oral feeds since
start of enteral feeds
Length of hospital stay (days)
Corrected gestational age at discharge (weeks)
Funding source This study was funded by the National Institutes of Health and by Medela, Inc., USA
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Additional information was provided by
the investigator: “we used a simple ran-
domization process (as described in Nurs-
ingResearch; Principles andMethods. Polit
& Hungler 1987 Chapter 8. Experiments
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Rodriguez 2011 (Continued)
and quasi-experiments, p 123). Random
assignment was carried out by writing the
word ”experimental“ on nine slips of pa-
per and the word ”control“ on 9 additional
pieces of paper. The eighteen pieces of pa-
per were placed in a box. On a separate
piece of paper, the numbers one through
eighteen were listed. The box was shaken,
and then each of these pieces of paper [was]
withdrawn, one at a time, and placed next
to a number in consecutive order. The fi-
nal list of eighteen numbers, which would
correspond to the eighteen potential sub-
jects, had either ”experimental“ or ”con-
trol“ written next to the number, which
would correspond to the group assignment
for each potential subject. The pieces of pa-
per were withdrawn from the box by the
principal investigator with a research nurse
serving as a witness. The randomization
process took place before any subjects were
enrolled in the study”
Allocation concealment (selection bias) Low risk The randomisation process took place be-
fore any participants were enrolled in the
study
“This list of randomized group assignment
was placed in a locked cabinet in a locked
room”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “were covered with an opaque tape as a
blinding procedure”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “were covered with an opaque tape as a
blinding procedure” and “specimens were
collected after the syringes were prepared”
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The study was blinded, and death is un-
likely is to be influenced
Incomplete outcome data (attrition bias)
All outcomes
Low risk The study author provided us with addi-
tional information, and intention-to-treat
analysis was conducted in this review
Incomplete outcome data (attrition bias)
Length of hospital stay
Low risk One control infant was excluded as this in-
fant received colostrum in error, and data
for 2 were excluded rather than used in an
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Rodriguez 2011 (Continued)
intention-to-treat analysis. The study au-
thor provided us with additional informa-
tion regarding that infant, and intention-
to-treat analysis was conducted in this re-
view
Selective reporting (reporting bias) Unclear risk Outcomes described in the methods were
reported in the results. The study protocol
is not available
Romano-Keeler 2016
Methods Open-label, randomised, controlled trial
Participants 99 infants (48 intervention and 51 control)
Inclusion criteria: gestational age < 32 weeks
Exclusion criteria: refusal to participate, enrolment in competing studies, Spanish-speak-
ing only
Setting: NICU, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Ten-
nessee, USA
From February 2013 to July 2014
Interventions Oral priming with mother’s colostrum - 0.1 mL colostrum administered to each cheek
every 6 hours for 5 days started in the first 48 hours of life (intervention) compared with
no oral priming with mother’s colostrum (control)
Outcomes Salivary immuno-peptides and oral microbiota
Necrotising enterocolitis (Bell’s stage 2 or 3)
Late-onset bacteraemia
Days to enteral feeds at 100 mL/kg/d
Days of antimicrobial exposure
Length of hospital stay (days)
Type of feeds at discharge
Funding source Vanderbilt University Medical Center and Thrasher Fund and NIH/NIGMS
(GM106143 (to JLW)), USA
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “preterm infants (< 32weeks’ completed ges-
tation) were randomised by a numeric list
generated a priori to receive oral priming
withmother’s colostrum or no oral priming”
32Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Romano-Keeler 2016 (Continued)
Allocation concealment (selection bias) Unclear risk No details were provided regarding alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was not blinded
“Participating staff members were not
blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was not blinded
“Participating staff members were not
blinded”, and assessors were not described
so presumably were also part of the clinical
team
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The study was not blinded, but death is un-
likely to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised infants were included in the
final analysis
Incomplete outcome data (attrition bias)
Length of hospital stay
Low risk Length of hospital stay was available for all
participants
Selective reporting (reporting bias) Low risk All outcomes described in the methods were
reported in the results. The protocol is avail-
able at clinicaltrials.gov (NCT01776268)
Sohn 2015
Methods Open-label, randomised, controlled trial
Participants 12 participants (6 intervention and 6 control)
Inclusion criteria: birth weight < 1500 grams, age < 7 days, intubated within 48 hours
of birth, maternal colostrum available
Exclusion criteria: a lethal medical condition
Setting: NICU, University of California Davis Children’s Hospital, Sacramento, Cali-
fornia, USA. From November 2013 to October 2014
Interventions 0.2 mL of the mother’s colostrum via sterile syringe into the baby’s oral cavity (0.1 mL
into each buccal pouch) every 2 hours for 46 hours. The comparison group received
routine care
Outcomes Oral microbiota
Necrotising enterocolitis (Bell’s stage 2 or 3)
Days to full enteral feeding
Duration of antibiotics (days)
Ventilator-associated pneumonia (diagnosed by positive culture on endotracheal aspirate)
Other pneumonia
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Sohn 2015 (Continued)
Chronic lung disease (defined as oxygen requirement at 36 weeks’ corrected gestational
age, or discharge, if sooner)
Early- and late-onset sepsis (diagnosed by positive blood cultures)
Death before discharge
Funding source University of California Davis, USA
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “neonates were randomly assigned to the
colostrum group”, but no details were given
on how this was done
Allocation concealment (selection bias) Low risk “neonates were randomly assigned to the
colostrum group using sealed opaque en-
velopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was not blinded
Blinding of outcome assessment (detection
bias)
Death before discharge to home
Low risk The study was not blinded, but death is un-
likely to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised infants were included in the
final analysis
Incomplete outcome data (attrition bias)
Length of hospital stay
Low risk This outcome was not reported in this study
Selective reporting (reporting bias) Low risk The study protocol was available at clinical-
trials.gov (NCT02306980). The pre-speci-
fied and expected outcomes of interest were
reported for all participants, except length of
stay, which was not reported
IgA: immunoglobulin A.
NCPAP: nasal continuous positive airway pressure.
NICU: neonatal intensive care unit.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez 2016 This study was found to be a non-randomised trial upon translation of the report from Spanish
Lee 2015 The mean age at which the study intervention was started was > 48 hours
Double-blind, placebo-controlled, randomised controlled trial conducted in the NICU, Seoul National Uni-
versity Children’s Hospital, in Seoul, Korea, including 48 infants born at < 28 weeks’ gestation. Every 3 hours
for 72 hours, 0.2 mL of colostrum or placebo (distilled water) was administered via the oropharyngeal route
using opaque syringes. Reported outcomes included necrotising enterocolitis (defined as Bell’s stage 2 or 3),
which occurred in 4 of 24 in the colostrum group and in 6 of 24 in the control group; and proven sepsis, which
occurred in 11 of 24 in the intervention group and in 14 of 24 in the control group. Three of the 24 infants in
the intervention group died as compared to 6 of 24 in the control group. However, this study is not included
in the review, as the study intervention was given after 48 hours of age to most participants
Montgomery 2008 This was an observational study conducted to determine the feasibility of oropharyngeal administration to very
low birth weight infants
Zhang 2017 The mean age at which the study intervention was started was > 48 hours in both groups
Double-blind, placebo-controlled, randomised controlled trial conducted in the NICU, Children’s Hospital,
Fudan University, in Shanghai, China. The study included infants with birth weight < 1500 grams who were
transferred into the hospital within 24 hours after birth and parents who agreed to provide colostrum. Infants
with a life-threatening condition and any disease that influenced enteral feeding were excluded. Those in the
intervention group received 0.1 mL of colostrum in each side of the cheek, and those in the control group
received normal saline in a similar manner. Outcomes reported included necrotising enterocolitis (defined as
Bell’s stage 2 or 3) and late-onset sepsis (defined as “bacterial growth occurred in at least one blood culture and
symptoms of clinical sepsis”). NEC was reported in 1 out of 32 infants in the intervention group and in 5 out
of 32 in the control group, and late-onset sepsis occurred in 4 out of 32 in the intervention group and in 8 out
of 32 in the control group. However, this study was excluded from the review as infants in both groups received
the first dose of study medication (colostrum or normal saline) after 48 hours of life
NEC: necrotising enterocolitis.
NICU: neonatal intensive care unit.
Characteristics of ongoing studies [ordered by study ID]
JPRN-UMIN000022923
Trial name or title The effect of oropharyngeal colostrum administration in preterm infants
Methods Parallel, double-blinded, randomised controlled trial
Participants Inclusion criteria: neonates born before 32 weeks’ gestation
Exclusion criteria: infants who cannot obtain colostrum within 72 hours, infants with congenital malforma-
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JPRN-UMIN000022923 (Continued)
tions, infants with chromosomal abnormalities
Setting: neonatal unit of Okayama University Hospital Pediatrics, Okayama, Japan
Interventions Intervention: 0.2 mL of mother’s colostrum administered from 72 hours after birth every 3 hours for 120
hours
Control: similar administration of saline
Outcomes Serum IgA, weight gain, length of hospital stay, carriage rate of MRSA, septicaemia
Starting date Not yet recruiting
Contact information Dr Yoshuke Wahio, 2-5-1,Shikatacho, Kitaku Okayamcity, Okayama, 700-8558, Japan
email: wxy-kk@hotmail.co.jp
Notes
Rodriguez 2015b
Trial name or title Oropharyngeal administration of mother’s colostrum, health outcomes of preterm infants: study protocol for
a randomised controlled trial
Methods Prospective, multi-centre, double-blind, placebo-controlled, randomised trial
Participants Extremely preterm infants with birth weight < 1250 grams, within the infant’s first 96 hours of life
Setting: 5 NICUs in hospitals within the United States
1. NorthShore University HealthSystem, Evanston, Illinois
2. Betty H. Cameron Women & Children’s Hospital, New Hanover Regional Medical Center, Wilmington,
North Carolina
3. St. Joseph’s Children’s Hospital, Paterson, New Jersey
4. Advocate Children’s Hospital, Park Ridge, Illinois
5. Morristown Medical Center, Morristown, New Jersey
Estimated enrolment: 622 participants, with an estimated dropout rate of 20%, allowing completed analysis
of 489 participants
Interventions Intervention group: oropharyngeal administration of mother’s colostrum
1. Initial treatment with 0.2 mL of colostrum administered per dose followed by buccal swabbing for 10
seconds. The procedure is repeated 2-hourly for 48 hours
2. Extended treatment period beginning immediately after completion of initial treatment. The procedure is
repeated every 3 hours until the infant reaches 32 weeks’ corrected gestational age
Comparison: sterile water given by the same procedure for colostrum
Outcomes Primary outcomes
1. Late-onset sepsis defined as new onset of at least 2 clinical symptoms with a positive blood culture (noted
after day of life 3) and identification of an organism known to be a cause of sepsis rather than a contaminant
2. NEC defined according to modified Bell’s criteria stage > 2 with clinical signs and radiological evidence
including any of the following: pneumatosis intestinalis or portal venous gas with or without pneumoperi-
toneum
3. Death
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Rodriguez 2015b (Continued)
Secondary outcomes
Faecal microbiota, urinary biomarker of oxidative stress, concentrations of urinary lactoferrin
Starting date November 2013
Contact information Nancy Rodriguez; nrodriguez@northshore.org
NorthShore University HealthSystem, Evanston, IL, USA
Notes This trial is actively recruiting
IgA: immunoglobulin A.
MRSA: methicillin-resistant Staphylococcus aureus.
NICU: neonatal intensive care unit.
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D A T A A N D A N A L Y S E S
Comparison 1. Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of necrotising
enterocolitis (NEC)
6 335 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.50, 4.02]
2 Incidence of late-onset infection 6 335 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.33]
3 Death before discharge to home 6 335 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.34, 1.71]
4 Days to full enteral feed 6 335 Mean Difference (IV, Fixed, 95% CI) -2.58 [-4.01, -1.14]
5 Length of hospital stay 4 293 Mean Difference (IV, Fixed, 95% CI) 0.81 [-5.87, 7.50]
6 Pneumonia 3 57 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.54, 8.06]
7 Reported adverse effects Other data No numeric data
8 Chronic lung disease (CLD) 4 206 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.60, 1.20]
8.1 CLD 3 57 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.40, 3.08]
8.2 CLD and BPD 1 149 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.57, 1.17]
9 Days of antibiotic therapy 3 140 Mean Difference (IV, Random, 95% CI) 1.69 [-2.00, 7.39]
10 Receiving any breast milk at
discharge to home.
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Fortified breast milk 1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.44, 1.02]
10.2 Unfortified breast milk 1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.89, 1.07]
10.3 Any breast milk (fortified
or unfortified)
1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.38, 0.97]
11 Days of parenteral nutrition 2 179 Mean Difference (IV, Fixed, 95% CI) 0.37 [-1.78, 2.52]
12 Weight at discharge to home 1 149 Mean Difference (IV, Fixed, 95% CI) 24.5 [-69.66, 118.
66]
13 Retinopathy of prematurity
(ROP)
2 165 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.33, 2.94]
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Analysis 1.1. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 1 Incidence of necrotising enterocolitis (NEC).
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 1 Incidence of necrotising enterocolitis (NEC)
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rodriguez 2011 0/9 0/7 Not estimable
McFadden 2012 0/11 0/18 Not estimable
Sohn 2015 2/6 1/6 18.8 % 2.00 [ 0.24, 16.61 ]
Romano˙x002d˙Keeler 2016 2/48 1/51 18.2 % 2.13 [ 0.20, 22.68 ]
NCT02912585 (1) 1/81 1/68 20.4 % 0.84 [ 0.05, 13.17 ]
Glass 2017 3/17 2/13 42.6 % 1.15 [ 0.22, 5.90 ]
Total (95% CI) 172 163 100.0 % 1.42 [ 0.50, 4.02 ]
Total events: 8 (OPC), 5 (Control)
Heterogeneity: Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours OPC Favours control
(1) Unpublished data provided by the author
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Analysis 1.2. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 2 Incidence of late-onset infection.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 2 Incidence of late-onset infection
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rodriguez 2011 3/9 0/7 1.7 % 5.60 [ 0.34, 93.35 ]
McFadden 2012 1/11 4/18 9.0 % 0.41 [ 0.05, 3.21 ]
Sohn 2015 1/6 2/6 5.9 % 0.50 [ 0.06, 4.15 ]
Romano˙x002d˙Keeler 2016 1/48 3/51 8.6 % 0.35 [ 0.04, 3.29 ]
NCT02912585 (1) 20/81 20/68 64.6 % 0.84 [ 0.49, 1.43 ]
Glass 2017 5/17 3/13 10.1 % 1.27 [ 0.37, 4.39 ]
Total (95% CI) 172 163 100.0 % 0.86 [ 0.56, 1.33 ]
Total events: 31 (OPC), 32 (Control)
Heterogeneity: Chi2 = 3.46, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours OPC Favours control
(1) Unpublished data provided by the author
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Analysis 1.3. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 3 Death before discharge to home.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 3 Death before discharge to home
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rodriguez 2011 2/9 0/7 4.5 % 4.00 [ 0.22, 72.01 ]
McFadden 2012 0/11 1/18 9.4 % 0.53 [ 0.02, 11.93 ]
Sohn 2015 0/6 1/6 12.1 % 0.33 [ 0.02, 6.86 ]
Romano˙x002d˙Keeler 2016 1/48 0/51 3.9 % 3.18 [ 0.13, 76.31 ]
NCT02912585 (1) 5/81 8/68 70.1 % 0.52 [ 0.18, 1.53 ]
Glass 2017 0/17 0/13 Not estimable
Total (95% CI) 172 163 100.0 % 0.76 [ 0.34, 1.71 ]
Total events: 8 (OPC), 10 (Control)
Heterogeneity: Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours OPC Favours control
(1) Unpublised data provided by the author
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Analysis 1.4. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 4 Days to full enteral feed.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 4 Days to full enteral feed
Study or subgroup OPC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rodriguez 2011 9 14.2 (5.7) 7 24.1 (8.6) 3.8 % -9.90 [ -17.28, -2.52 ]
McFadden 2012 11 11.2 (3.9) 18 11.9 (8.2) 10.5 % -0.70 [ -5.13, 3.73 ]
Sohn 2015 6 23.1 (11.7) 6 13.8 (5.9) 1.9 % 9.30 [ -1.18, 19.78 ]
Romano˙x002d˙Keeler 2016 48 13.1 (6.8) 51 14.5 (8.1) 23.9 % -1.40 [ -4.34, 1.54 ]
NCT02912585 (1) 81 20.7 (6.5) 68 24 (5.1) 59.5 % -3.30 [ -5.16, -1.44 ]
Glass 2017 17 24.2 (32.5) 13 24.9 (33.8) 0.4 % -0.70 [ -24.71, 23.31 ]
Total (95% CI) 172 163 100.0 % -2.58 [ -4.01, -1.14 ]
Heterogeneity: Chi2 = 10.62, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 3.51 (P = 0.00044)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours OPC Favours Control
(1) Unpublished data provided by the author
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Analysis 1.5. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 5 Length of hospital stay.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 5 Length of hospital stay
Study or subgroup OPC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rodriguez 2011 9 101.43 (44.26) 7 85.33 (32.96) 3.1 % 16.10 [ -21.75, 53.95 ]
McFadden 2012 11 69.4 (35) 18 47.18 (22.95) 8.3 % 22.22 [ -1.02, 45.46 ]
Romano˙x002d˙Keeler 2016 48 56 (35) 51 65 (35) 23.5 % -9.00 [ -22.80, 4.80 ]
NCT02912585 (1) 81 65.4 (29.28) 68 64.5 (22.22) 65.1 % 0.90 [ -7.38, 9.18 ]
Total (95% CI) 149 144 100.0 % 0.81 [ -5.87, 7.50 ]
Heterogeneity: Chi2 = 5.83, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours OPC Favours control
(1) Unpublished data provided by the author
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Analysis 1.6. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 6 Pneumonia.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 6 Pneumonia
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sohn 2015 2/6 0/6 16.7 % 5.00 [ 0.29, 86.43 ]
Rodriguez 2011 3/9 0/7 18.6 % 5.60 [ 0.34, 93.35 ]
McFadden 2012 0/11 2/18 64.7 % 0.32 [ 0.02, 6.04 ]
Total (95% CI) 26 31 100.0 % 2.08 [ 0.54, 8.06 ]
Total events: 5 (OPC), 2 (Control)
Heterogeneity: Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours OPC Favours Control
Analysis 1.7. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 7 Reported adverse effects.
Reported adverse effects
Study Outcome Definition Comments
Glass 2017 No adverse effects reported. Infants were monitored for apnea,
bradycardia and aspiration pneu-
monia
“There were no apenic,
bradycardic events reported with
oropharyngeal colostrum or sterile
water administration.”
McFadden 2012 No adverse effects have been re-
ported
Nopre-defined adverse effects have
been described in the study
Adverse effects were narratively re-
ported as no adverse effects with
the intervention. No numerical
data were provided
NCT02912585 No adverse effects have been re-
ported
Nopre-defined adverse effects have
been described in the study
“The subjects tolerated the inter-
vention and there were no ad-
verse effects during the protocol
treatment. No numerical data pro-
vided.”
Rodriguez 2011 No adverse effects have been re-
ported
Nopre-defined adverse effects have
been described in the study
“All subjects tolerated the inter-
vention and therewere no recorded
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Reported adverse effects (Continued)
episodes of apnea, bradycardia, hy-
potension, desaturation or other
adverse effects during the treat-
ment protocol”. No numerical
data were provided
Romano-Keeler 2016 No adverse effects have been re-
ported
Nopre-defined adverse effects have
been described in the study
“No adverse events were noted
among patients in either group
during the course of the study”.No
numerical data were provided
Sohn 2015 No adverse effects have been re-
ported
Nopre-defined adverse effects have
been described in the study
No data or comment in the report.
Analysis 1.8. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 8 Chronic lung disease (CLD).
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 8 Chronic lung disease (CLD)
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 CLD
Rodriguez 2011 2/9 1/7 2.7 % 1.56 [ 0.17, 13.87 ]
McFadden 2012 (1) 1/11 3/18 5.5 % 0.55 [ 0.06, 4.61 ]
Sohn 2015 3/6 2/6 4.8 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 26 31 13.1 % 1.11 [ 0.40, 3.08 ]
Total events: 6 (OPC), 6 (Control)
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 CLD and BPD
NCT02912585 32/81 33/68 86.9 % 0.81 [ 0.57, 1.17 ]
Subtotal (95% CI) 81 68 86.9 % 0.81 [ 0.57, 1.17 ]
Total events: 32 (OPC), 33 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 107 99 100.0 % 0.85 [ 0.60, 1.20 ]
0.02 0.1 1 10 50
Favours OPC Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 38 (OPC), 39 (Control)
Heterogeneity: Chi2 = 1.16, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.37)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
0.02 0.1 1 10 50
Favours OPC Favours control
(1) 4 infants have CLD not reported to which group
Analysis 1.9. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 9 Days of antibiotic therapy.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 9 Days of antibiotic therapy
Study or subgroup OPC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McFadden 2012 11 12 (2.8) 18 5 (4.3) 34.8 % 7.00 [ 4.41, 9.59 ]
Sohn 2015 6 2.5 (2.3) 6 4.3 (5.7) 29.3 % -1.80 [ -6.72, 3.12 ]
Romano˙x002d˙Keeler 2016 48 3.9 (5.1) 51 4.5 (5) 35.9 % -0.60 [ -2.59, 1.39 ]
Total (95% CI) 65 75 100.0 % 1.69 [ -4.00, 7.39 ]
Heterogeneity: Tau2 = 22.47; Chi2 = 23.18, df = 2 (P<0.00001); I2 =91%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours OPC Favours control
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Analysis 1.10. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 10 Receiving any breast milk at discharge to home..
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 10 Receiving any breast milk at discharge to home.
Study or subgroup OPC Control
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fortified breast milk
Romano˙x002d˙Keeler 2016 (1) 29/48 21/51 100.0 % 0.67 [ 0.44, 1.02 ]
Subtotal (95% CI) 48 51 100.0 % 0.67 [ 0.44, 1.02 ]
Total events: 29 (OPC), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 Unfortified breast milk
Romano˙x002d˙Keeler 2016 (2) 3/48 2/51 100.0 % 0.98 [ 0.89, 1.07 ]
Subtotal (95% CI) 48 51 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 3 (OPC), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 Any breast milk (fortified or unfortified)
Romano˙x002d˙Keeler 2016 32/48 23/51 100.0 % 0.61 [ 0.38, 0.97 ]
Subtotal (95% CI) 48 51 100.0 % 0.61 [ 0.38, 0.97 ]
Total events: 32 (OPC), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
0.1 0.2 0.5 1 2 5 10
Favours control Favours OPC
(1) Unpublished data provided by the author
(2) Unpublished data provided by the author
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Analysis 1.11. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 11 Days of parenteral nutrition.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 11 Days of parenteral nutrition
Study or subgroup OPC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
NCT02912585 (1) 81 14.39 (5.75) 68 14 (7.4) 99.1 % 0.39 [ -1.77, 2.55 ]
Glass 2017 17 22.1 (28.86) 13 23.6 (33.17) 0.9 % -1.50 [ -24.16, 21.16 ]
Total (95% CI) 98 81 100.0 % 0.37 [ -1.78, 2.52 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours OPC Favours control
(1) Unpublished data provided by the author. The mean and SD were estimated.
Analysis 1.12. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 12 Weight at discharge to home.
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 12 Weight at discharge to home
Study or subgroup OPC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
NCT02912585 (1) 81 2184.5 (336.3637) 68 2160 (248.89) 100.0 % 24.50 [ -69.66, 118.66 ]
Total (95% CI) 81 68 100.0 % 24.50 [ -69.66, 118.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours OPC Favours control
(1) Unpublished data provided by the author
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Analysis 1.13. Comparison 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no
intervention), Outcome 13 Retinopathy of prematurity (ROP).
Review: Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants
Comparison: 1 Oropharyngeal colostrum (OPC) versus control (water, saline, or no intervention)
Outcome: 13 Retinopathy of prematurity (ROP)
Study or subgroup OPC Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rodriguez 2011 (1) 0/9 1/7 27.7 % 0.27 [ 0.01, 5.70 ]
NCT02912585 6/81 4/68 72.3 % 1.26 [ 0.37, 4.28 ]
Total (95% CI) 90 75 100.0 % 0.98 [ 0.33, 2.94 ]
Total events: 6 (OPC), 5 (Control)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours OPC Favours control
(1) Additional information provided by the author.
A D D I T I O N A L T A B L E S
Table 1. Characteristics of participants in the included studies
Criteria Rodriguez 2011 McFadden 2012 Sohn 2015 Romano-Keeler
2016
NCT02912585 Glass 2017
Number of par-
ticipants
16 27 12 99 149 30
Gestational age
(weeks)
25-28 27-32 25-30 28-31 26-31 27-29
Birth weight
(grams)
410-1250 590-2530 490-1300 905-1602 787-1217 1020-1169
Table 2. Adverse effects
Study ID Outcome Definition Comments
Rodriguez 2011 No adverse effects reported No pre-defined adverse effects de-
scribed in the study
“All subjects tolerated the interven-
tion and there were no recorded
episodes of apnea, bradycardia, hy-
potension, desaturation or other ad-
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Table 2. Adverse effects (Continued)
verse effects during the treatment pro-
tocol”
No numerical data were provided
McFadden 2012 No adverse effects reported No pre-defined adverse effects de-
scribed in the study
Adverse effects were narratively re-
ported as no adverse effects with the
intervention
No numerical data were provided
Sohn 2015 No adverse effects reported No pre-defined adverse effects de-
scribed in the study
No data or comment in the report
Romano-Keeler 2016 No adverse effects reported No pre-defined adverse effects de-
scribed in the study
“No adverse events were noted among
patients in either group during the
course of the study”
No numerical data were provided
NCT02912585 No adverse effects reported No pre-defined adverse effects de-
scribed in the study
“The subjects tolerated the interven-
tion and there were no adverse effects
during the protocol treatment”
No numerical data were provided
Glass 2017 No adverse effects reported Infants monitored for apnoea, brady-
cardia, and aspiration pneumonia
“There were no apneic, bradycardic
events reported with oropharyngeal
colostrum or sterile water administra-
tion”
A P P E N D I C E S
Appendix 1. Cochrane Neonatal standard search strategy
The search term ’colostrum’ was used in combination with the following searches in the different databases.
PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR
LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo
[tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh]))
Embase: ((exp infant) OR (infan* OR newborn or neonat* OR premature or very low birth weight or low birth weight or VLBW
or LBW).mp AND (human not animal) AND (randomized controlled trial or controlled clinical trial or randomized or placebo or
clinical trials as topic or randomly or trial or clinical trial).mp
CINAHL: (infan* OR newborn OR neonat* OR premature OR low birth weight ORVLBWOR LBW) AND (randomized controlled
trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)
Cochrane Library: (infan* or newborn or neonat* or premature or preterm or very low birth weight or low birth weight or VLBW or
LBW)
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Appendix 2. Risk of bias tool
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
• low risk (any truly random process, e.g. random number table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or
• unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
• unclear risk
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding was assessed separately for different outcomes or class of outcomes. We categorised the
methods as:
• low risk, high risk, or unclear risk for participants; and
• low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we categorised the methods used to blind outcome assessment. Blinding was assessed separately for different
outcomes or classes of outcomes. We categorised the methods as:
• low risk for outcome assessors;
• high risk for outcome assessors; or
• unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were
incomplete outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with total
randomised participants), reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or
were related to outcomes. When sufficient information was reported or supplied by trial authors, we re-included missing data in the
analyses. We categorised the methods as:
• low risk (< 20% missing data);
• high risk (≥ 20% missing data); or
• unclear risk.
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. For
studies in which study protocols were published in advance, we compared pre-specified outcomes versus outcomes eventually reported
in the published results. If the study protocol was not published in advance, we contacted study authors to gain access to the study
protocol. We assessed the methods as:
• low risk (when it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review have
been reported);
• high risk (when not all of the study’s pre-specified outcomes have been reported; one or more reported primary outcomes were
not pre-specified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported); or
• unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at high risk of bias?
For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether a potential
source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We
assessed whether each study was free of other problems that could put it at risk of bias as:
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• low risk;
• high risk; or
• unclear risk.
If needed, we explored the impact of the level of bias by undertaking sensitivity analyses.
C O N T R I B U T I O N S O F A U T H O R S
Dr Nasuf wrote the protocol, and Drs Dorling and Ojha reviewed and edited it. Drs Nasuf and Ojha independently determined the
eligibility of identified studies, assessed the methodological quality of included trials, and extracted and analysed the data. Dr Nasuf
entered the data into RevMan, created the SoF table, wrote to study authors for additional information, obtained additional data from
the included studies, and updated the search. Drs Nasuf and Ojha wrote the manuscript. Dr Dorling checked data extraction, resolved
differences in opinion, and reviewed and edited the manuscript.
D E C L A R A T I O N S O F I N T E R E S T
The review authors have no conflicts of interest to declare.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Editorial support for Cochrane Neonatal has been funded by a UK National Institute of Health Research (NIHR) Cochrane
Programme Grant (16/114/03). The views expressed in this publication are those of the review authors and not necessarily those of
the National Health Service, the NIHR, or the UK Department of Health.
• Vermont Oxford Network, USA.
Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a worldwide collaboration of health
professionals dedicated to providing evidence-based care of the highest quality for newborn infants and their families.
52Oropharyngeal colostrum in preventing mortality and morbidity in preterm infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
